Science World Honors Kevan Shokat for High-Impact Cancer Research

The UC San Francisco scientist who developed a successful approach to drugging a protein produced by the mutated KRAS gene has won two prestigious awards in the opening weeks of 2023. The discovery, made by Kevan Shokat, PhD, in 2013 opened up new avenues for cancer treatment and research. Mutations

“Smarter” Breast Cancer Screening Measures Risk Down to Your DNA

A novel UC San Francisco study that aims to transform breast cancer screening is expanding to reach women as young as 30, with the intention of including thousands of women who could be at higher risk of developing aggressive cancer. The expanded study, known as WISDOM 2.0, is testing a personalized

If Immunity Is Innate, What Impacts Our Ability to Fight Infections?

As an assistant professor of pharmaceutical chemistry at UC San Francisco, Balyn Zaro, PhD, is drawn to genetic differences in the innate immune system. After all, those differences can impact the effectiveness of the medications we take. Her lab investigates the cause and consequence of genetic

Aggressive Surgery Increases Survival with Low-Grade Brain Tumors

The transition of a low-grade, slow growing brain tumor to a lethal one can be delayed if neurosurgeons remove as much as possible soon after diagnosis, according to the results of a study led by UC San Francisco. The findings run counter to other research indicating that extensive resection, or

Duping Antibodies with a Decoy, Researchers Aim to Prevent Rejection of Transplanted Cells

Researchers at UC San Francisco (UCSF) have developed a novel, potentially life-saving approach that may prevent antibodies from triggering immune rejection of engineered therapeutic and transplant cells. Rejection mediated by antibodies—as opposed to the chemical assault initiated by immune cells

UCSF Researchers Uncover New Pathway for Molecular Cancer Drug Therapies

A fundamental challenge in drug development is the balance between optimizing a drug’s lock-and-key fit with its target and the drug’s ability to make its way across the cellular membrane and access that target. The search for cell-permeable drugs has conventionally focused on low-molecular weight

Rethinking How Cancer Cells Evade Targeted Therapy

Glioblastomas (GBMs) are incurable brain tumors with a prognosis of about one-and-a half years on average. They are highly resistant to treatment and have defied all attempts at precision therapy. In their study published December 20 in Nature Cancer, first author Lin Wang, PhD and senior author